Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for vontrol of ovarian cancer

Molecular Therapy

Volumn 17, Issue 8, 2009, Pages 1365-1372

  Chang, Chih Long ^a,b   Ma, Barbara ^a   Pang, Xiaowu ^c   Wu, T C ^a,d   Hung, Chien Fu ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c HOWARD UNIVERSITY   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LUCIFERASE; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; ROFECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TARGETING; GENE TRANSFER; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; SERODIAGNOSIS; VACCINIA; VACCINIA VIRUS;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; VACCINIA VIRUS;

MUS; VACCINIA VIRUS;

EID: 68249122152     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.118     Document Type: Article

References (40)

1. Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Smigal, C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
2. Schwartz, PE (2002). Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 107: 99-118.
3. Hung, CF, Tsai, YC, He, L, Coukos, G, Fodor, I, Qin, L et al. (2007). Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 14: 20-29.
4. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358.
5. Kirn, DH, Wang, Y, Liang, W, Contag, CH and Thorne, SH (2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 68: 2071-2075.
6. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
7. Ryan, EP, Bushnell, TP, Friedman, AE, Rahman, I and Phipps, RP (2008). Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother 57: 347-358.
8. Zhi, YH, Liu, RS, Song, MM, Tian, Y, Long, J, Tu, W et al. (2005). Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 11: 3724-3728.
9. Ryan, EP, Pollock, SJ, Pollack, SJ, Murant, TI, Bernstein, SH, Felgar, RE et al. (2005). Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 174: 2619-2626.
10. Ryan, EP, Malboeuf, CM, Bernard, M, Rose, RC and Phipps, RP (2006). Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J Immunol 177: 7811-7819.
11. Niki, Y, Takaishi, H, Takito, J, Miyamoto, T, Kosaki, N, Matsumoto, H et al. (2007). Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J Immunol 179: 639-646.
12. Xie, H, Gao, L, Chai, N, Song, J, Wang, J, Song, Z et al. (2008). Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol carcinog 48: 56-65.
13. Vital-Reyes, V, Rodríguez-Burford, C, Chhieng, DC, Oelschlager, DK, Reyes-Fuentes, A, Barnes, M et al. (2006). Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med Res 37: 689-695.
14. Liou, JY, Ghelani, D, Yeh, S and Wu, KK (2007). Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res 67: 3185-3191.
15. Howe, LR, Subbaramaiah, K, Patel, J, Masferrer, JL, Deora, A, Hudis, C et al. (2002). Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/ neu-induced breast cancer. Cancer Res 62: 5405-5407.
16. Lanza-Jacoby, S, Miller, S, Flynn, J, Gallatig, K, Daskalakis, C, Masferrer, JL et al. (2003). The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12: 1486-1491.
17. Ding, H, Han, C, Zhu, J, Chen, CS and D'Ambrosio, SM (2005). Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113: 803-810.
18. Jendrossek, V, Handrick, R and Belka, C (2003). Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17: 1547-1549.
19. Johnson, AJ, Smith, LL, Zhu, J, Heerema, NA, Jefferson, S, Mone, A et al. (2005). A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105 2504-2509.
20. Funakoshi-Tago, M, Shimizu, T, Tago, K, Nakamura, M, Itoh, H, Sonoda, Y, et al. (2008). Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem pharmacol 76: 662-671.
21. Xin, B, Yokoyama, Y, Shigeto, T, Futagami, M and Mizunuma, H (2007). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110: 791-800.
22. Farooqui, M, Li, Y, Rogers, T, Poonawala, T, Griffin, RJ, Song, CW et al. (2007). COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97 1523-1531.
23. Masferrer, JL, Leahy, KM, Koki, AT, Zweifel, BS, Settle, SL, Woerner, BM et al. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311.
24. Kang, KB, Wang, TT, Woon, CT, Cheah, ES, Moore, XL, Zhu, C et al. (2007). Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67: 888-896.
25. Shin, YK, Park, JS, Kim, HS, Jun, HJ, Kim, GE, Suh, CO et al. (2005). Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65: 9501-9509.
26. Nakata, E, Mason, KA, Hunter, N, Husain, A, Raju, U, Liao, Z et al. (2004). Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58: 369-375.
27. Raju, U, Nakata, E, Yang, P, Newman, RA, Ang, KK and Milas, L (2002). In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int J Radiat Oncol Biol Phys 54: 886-894.
28. Pyo, H, Choy, H, Amorino, GP, Kim, JS, Cao, Q, Hercules, SK et al. (2001). A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7: 2998-3005.
29. van Wijngaarden, J, van Beek, E, van Rossum, G, van der Bent, C, Hoekman, K, van der Pluijm, G et al. (2007). Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43: 433-442.
30. Altorki, NK, Keresztes, RS, Port, JL, Libby, DM, Korst, RJ, Flieder, DB et al. (2003). Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21: 2645-2650.
31. Haas, AR, Sun, J, Vachani, A, Wallace, AF, Silverberg, M, Kapoor, V et al. (2006). Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12: 214-222.
32. Zeytin, HE, Patel, AC, Rogers, CJ, Canter, D, Hursting, SD, Schlom, J et al. (2004). Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 64: 3668-3678.
33. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 9: 533-542.
34. Liu, TC, Hwang, T, Park, BH, Bell, J and Kirn, DH (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16: 1637-1642.
35. Howes, LG (2007). Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag 3 831-845.
36. Carothers, AM, Moran, AE, Cho, NL, Redston, M and Bertagnolli, MM (2006). Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 66: 6432-6438.
37. Yu, YA, Galanis, C, Woo, Y, Chen, N, Zhang, Q, Fong, Y et al. (2009). Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8: 141-151.
38. Roby, KF, Taylor, CC, Sweetwood, JP, Cheng, Y, Pace, JL, Tawfik, O et al. (2000). Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.
39. Chen, B, Timiryasova, TM, Haghighat, P, Andres, ML, Kajioka, EH, Dutta-Roy, R et al. (2001). Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 24: 46-57.
40. Wu, TC, Guarnieri, FG, Staveley-O'Carroll, KF, Viscidi, RP, Levitsky, HI, Hedrick, L et al. (1995). Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92: 11671-11675.